Daily editorial coverage of AI aimed at aging biology, genomics, and therapies that try to change disease course — sourced for practicing clinicians, with research caveats where they matter.
Read today’s featured story
New genomic language models, organ-aging genetics, and disease-modifying CRISPR/base-editing clinical paths — rotated off yesterday’s AlphaGenome lead.
A phylogeny-aware genomic language model (Nature, 9 Sep 2026) improves coding and non-coding variant-effect prediction, pathogenic/GWAS prioritization, and rare-variant association power — useful context for clinicians following computational genetics, not a bedside test.
Caveat: Research model; not designed or validated for direct clinical decision-making.
Editorial summary only. Research models ≠ cleared clinical devices. Verify against primary sources and your institution’s evidence standards.
Real headlines with outbound sources. Past days live in the archive.
UK Biobank n=53,014 proteomic clocks linked to disease/environment and GWAS loci (Nature Communications, 9 Sep 2026); immune and liver show strongest cross-organ genetic connectivity; externally checked in China Kadoorie Biobank.
Caveat: Observational/genetic atlas — not an approved aging therapy or surrogate endpoint for lifespan.
Nature Communications →Intellia’s lonvoguran ziclumeran (KLKB1) accepted with priority review; PDUFA-style decision target ~10 Mar 2027. Phase 3 HAELO: ~87% lower attack rate vs placebo; 62% attack-free over ~6 months in treated arm. Could become first FDA-approved in vivo CRISPR if cleared.
Caveat: Not yet approved; longer-term safety/efficacy still under review.
Angioedema News → CRISPR Medicine News →Cleveland Clinic–led Phase 1 / CRISPR Therapeutics data (ESC 2026 + NEJM correspondence): single IV infusion; at highest dose ~52–53% LDL and ~48% triglyceride reductions sustained at 12 months; no therapy-related SAEs in that follow-up window (n=15 Phase 1a).
Caveat: Early, small, lipid-disorder cohort — not proven CV outcome benefit; long-term gene-edit safety follow-up continues.
Cleveland Clinic → BioSpace / CRISPR Tx →Cell Stem Cell (7 Sep 2026) — CorrectSequence transformer Base Editor therapies inducing HbF; extension cohort (SCD + TDT from diverse ancestries) with transfusion independence / VOC-free follow-up in reported patients; company also cites broader early program experience. Differentiates from nuclease Casgevy narrative already archived.
Caveat: Small early-phase / extension data; not a marketing authorization; larger pivotal evidence still needed.
PR Newswire → Pharmacally summary →Phylogeny-aware genomic LM improves coding/non-coding variant-effect prediction and rare-variant association power — computational-genetics context for clinicians, not a bedside assay.
Caveat: Research model; not designed or validated for direct clinical decision-making.
Nature article → Berkeley News →Genomic LMs, organ-aging clocks, and early CRISPR/base-editing programs are different evidence classes. This site keeps them labeled so a headline never collapses into “AI cured aging.”
Browse prior editions →Virile.ai is an editorial front door for doctors and clinical leaders — longevity biology, genomics, and disease-modifying AI — without a prescription checkout or consumer funnel. No public contact form.
Homepage always shows the latest longevity / genes / cures cards.
Prior daily editions stay readable with dates and source links.
Open the primary paper, FDA letter, or trial report before practice change.
Not medical advice. Not an FDA communication. Not affiliated with Nature journals, Intellia, CRISPR Therapeutics, CorrectSequence, Cleveland Clinic, the FDA, or companies named in story cards.
When the daily set rotates, prior stories move to the archive with their date and sources intact.